Skip to content

Zymeworks ZYME Debt-to-assets

Debt-to-assets at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.0×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
0.1×+0.1×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
0.0×

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Calculated from Zymeworks’s reported figures.

Based on the most recent quarter.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's debt-to-assets?
Zymeworks (ZYME) reported debt-to-assets of 0× in Q1 2026.
How has Zymeworks's debt-to-assets changed year-over-year?
Zymeworks's debt-to-assets decreased by 18.0% year-over-year, from 0× to 0×.
What is the long-term trend for Zymeworks's debt-to-assets?
Over 4 years (2021 to 2025), Zymeworks's debt-to-assets has grown at a -10.8% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.